查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1834078

冠状动脉疾病治疗设备市场（按设备类型、治疗类型、方法和最终用户划分）—2025-2032 年全球预测

Coronary Artery Disease Treatment Devices Market by Device Type, Treatment Type, Approach, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年冠状动脉疾病治疗设备市场将成长至 72.6 亿美元，复合年增长率为 5.92%。

主要市场统计数据
基准年2024年 45.8亿美元
预计2025年 48.4亿美元
预测年份：2032年 72.6亿美元
复合年增长率（%） 5.92%

对重塑冠状动脉疾病治疗方法的临床复杂性、设备创新途径和医疗保健重点的权威概述

在技​​术创新、手术偏好变化以及医疗服务模式转变的共同影响下，冠状动脉疾病治疗设备的临床和商业性格局正在迅速演变。患者的病症日益复杂，包括高度钙化病变、慢性完全阻塞和合併症，需要细緻入微的治疗方法。同时，临床医生正在将更高解析度的血管内影像和生理工具整合到日常决策中，以提高手术准确性和长期疗效。

在这样的临床背景下，器械开发商和医疗保健系统正在平衡多项重要因素：提高急性手术成功率、减少再次手术，以及展现符合付款方期望的持续患者获益。器械设计的进步，例如用于矫正钙化斑块的精密动脉粥状硬化斑块切除术样硬化切除术和用于抑制血管再阻塞的增强型药物输送球囊技术，与有利于微创入路和缩短住院时间的手术流程转变相辅相成。应对这些动态变化需要一种跨职能策略，将临床证据产生、监管途径、报销定位和供应链弹性连结起来。

本执行摘要总结了目前影响冠状动脉器械的驱动因素，并指出了可能影响产品采用、临床实践和商业策略的结构性变化。本分析将临床创新置于卫生系统优先事项和营运现实的背景下，为高阶主管和临床领导者提供结构性基础，使其能够根据不断变化的未满足需求调整投资。

影像学、生理学、斑块修饰和手术入路趋势如何融合，重新定义冠状动脉治疗的治疗基准和设备采用

冠状动脉介入治疗的构思、设计和实施方式正在发生数次变革。这些变革正在加速影像学、生理学和治疗设备功能的融合。首先，血管内影像学和生理学评估正从可选的辅助手段转变为病例规划和优化的核心组成部分。血管内超音波和光同调断层扫瞄的广泛应用，以及基于血流储备分数的决策，正在提高病灶层面的诊断准确性，并使更有针对性的设备选择和置入策略成为可能。

其次，复杂病变（尤其是钙化性冠状动脉疾病）的增多，推动了对专用斑块修復工具的需求。包括雷射、轨道和旋转在内的动脉粥状硬化斑块切除术技术正在不断改进，以提高安全性并整合辅助性治疗。同时，药物释放型支架技术和药物涂层球囊也在不断发展，其聚合物和药物配方也在不断改进，旨在延长球囊的耐用性，同时最大限度地减少晚期不利事件。这些设备的进步正在鼓励在单一病例中结合多种互补技术的混合手术策略。

第三，为了减少血管併发症并提高病患吞吐量，许多医疗中心正在转向使用桡动脉路径进行手术。这种转变正在改变与轮廓、输送能力和扭矩控制相关的器械设计考虑。最后，医疗保健领域的数位化和数据主导转型，包括手术分析和真实世界证据生成，使製造商能够透过记录长期疗效、经济影响和生活品质改善来展示超越手术成功的价值。竞争性基准化分析正在重塑竞争动态，并为临床证据和器械性能建立新的基准。

评估美国关税调整对冠状动脉设备供应链和定价策略的累积营运、采购和监管影响

2025年美国关税和贸易政策的实施将对器械采购、定价策略和供应链架构产生累积影响，促使产业相关人员重新评估其营运模式。向受影响国家和地区供应零件和成品的製造商面临利润压力，因此他们加快了供应商多元化和探索近岸外包选项的步伐。这些调整强调了双重采购策略、替代供应商的资格认定以及库存优化，以保持临床供应的连续性。

同时，采购部门和卫生系统重组了合约框架，以应对潜在的成本波动。透过协商签订长期合约和价格保护条款，以降低风险敞口，同时一些买家采取了更积极的库存管理和需求预测，以减少采购摩擦。关税也更加重视製造业的韧性，鼓励对美洲区域製造能力和製造外包伙伴关係的投资。

产品重新贴标、原产国文件变更以及物流路线变更增加了行政管理的复杂性以及监管和合规负担。为了因应这种情况，企业利用跨职能团队，结合监管、品质和供应链专业知识，加速变更管理并维持监管合规性。从策略上讲，关税的累积影响迫使许多公司优先考虑产品设计和筹资策略，以最大限度地减少受关税影响的成分，加快本地资格确认工作，并利用临床疗效证据在受限的报销环境中保护定价权。

深入的細項分析将设备模式、治疗途径、获取策略和医疗保健环境与采用机会和产品定位联繫起来

细緻的细分镜头揭示了跨装置类型、治疗方式、程序方法和最终用户设定的不同机会区和操作考虑因素。按类型对设备进行分类需要分析动脉粥状硬化斑块切除术系统，包括雷射、轨道和旋转迭代。球囊导管技术包括切割、药物涂层和标准设计，药物涂层球囊与支架内血管再阻塞和小血管疾病的关係越来越密切。导管导引线，根据病变复杂性和输送需求发挥不同的作用。血管内成像系统包括分数流量储备平台、血管内超音波和光同调断层扫瞄，每个系统都提供独特的诊断分辨率，以指导设备选择和部署技术。支架平台包括裸金属结构、生物可吸收支架和药物释放型设计，急性支架、长期血管癒合和设备寿命之间的权衡决定了临床医生的偏好。

在考虑治疗类型时，冠状动脉绕道手术手术仍是某些解剖和多支血管病变的必要选择，非体外循环和体外循环策略仍保留一定的临床原理。经皮介入治疗，无论是单独球囊血管成形术或联合置入术，其范围都在随着辅助技术和操作的改进而不断扩大。随着多学科心臟团队评估和病变水平诊断的提高，手术和经皮治疗之间的选择也越来越个人化。

经股动脉或经桡动脉入路的选择会影响器械设计和手术物流，因为桡动脉优先的实践优先考虑低调、易于输送的器械，而股动脉入路可能需要使用笨重的辅助器具。门诊手术中心、心臟中心和医院的终端使用者细分反映了不同的手术复杂性、资源密集度和报销考量，从而形成了差异化的采用路径。每个细分领域都需要量身定制的证据产生、定价策略和服务模式，以优化在异质临床环境中的采用。

美洲、欧洲、中东和非洲以及亚太地区的区域动态将影响各地区的监管途径、采用重点和商业化策略

美洲、欧洲、中东和非洲以及亚太地区的区域动态创造了独特的需求驱动因素和业务需求，塑造了监管格局、报销格局和临床实践模式。在美洲，程序创新通常与注重实际结果和成本效益的综合支付系统和大型医院网络交叉。这种环境奖励商投资于强有力的上市后证据和医疗保健提供者教育计划，以将设备优势转化为可衡量的临床和经济价值。

欧洲、中东和非洲地区监管和报销框架的差异性使得制定区域性打入市场策略成为必要。西方市场通常需要严格的医疗技术评估和针对特定国家的临床证据，而该地区的新兴市场可能更注重成本控制和可扩展的解决方案。在该地区发展的製造商必须根据不同国家医疗保健体系的期望，量身定制定价、临床支援和监管提交方案。

亚太地区拥有庞大的手术市场和快速发展的临床能力，多个国家对介入性心臟病学基础设施进行了大规模投资。本地製造和伙伴关係关係尤其重要，因为区域供应链整合和监管协作将加速该领域的应用。各地区人口结构变化——人口老化和心血管疾病负担的增加——正在推动持续的临床需求，但区域报销、医护人员培训和卫生系统的优先事项将决定设备应用的速度和性质。

产品整合、临床证据、供应链稳健性和商业化专业知识如何定义冠状动脉设备製造商的竞争优势

活跃于冠状动脉器械研发领域的公司之间的竞争动态取决于技术领导力、临床证据生成、生产规模和市场敏锐度的整合。领先的公司优先考虑整合治疗设备和诊断平台的整合产品组合，从而提供捆绑式流程解决方案，以支援更优的病例选择和最佳化。随着医疗体系越来越重视长期疗效和经济价值的展现，对临床试验、註册和上市后监测的投资将持续成为差异化因素。

策略伙伴关係、授权协议和选择性收购是获取互补技术、扩大地域覆盖范围或加速进入新医疗程序利基市场的常见途径。供应链弹性和监管敏捷性是管理的首要任务，企业透过製造外包网路和区域生产能力来建立冗余。在临床营运、证据产生和报销专业知识方面的人才投资对于将设备性能转化为采用和有利的采购结果同样重要。

产品差异化日益聚焦于可交付性、特异性病变的性能以及辅助诊断相容性。提供临床医生培训计划、程序支援和强大数据收集能力的公司，将有望加速技术应用并获得长期临床认可。随着竞争格局的成熟，那些能够将技术创新与切实可行的商业化模式相结合，并反映临床医生工作流程和付款人期望的公司将成为赢家。

领导者需要采取实际的策略措施，协调产品创新、供应链弹性和以证据主导的商业化，以实现永续成长

为了获取持续价值，产业领导者应优先制定产品组合策略，强调具有临床意义的差异化、监管前瞻性和供应链适应性。首先，选择性地投资于能够解决临床影响缺口（例如钙化病变、小血管疾病和血管再阻塞）的设备改进，同时确保设计改进能够增强桡动脉入路的可及性。能够产生随机证据和真实世界註册数据的合作临床计画将强化对临床医生和付款人的价值提案，并支持更广泛的应用和报销协调。

其次，我们建构了一个富有弹性的采购架构，透过审核多家供应商、探索区域製造伙伴关係以及纳入关税感知采购条款来缓解政策引发的成本衝击。跨职能团队负责快速变更管理流程，在确保合规性的同时加快供应商入职。第三，我们将产品发布与整合血管内成像和生理学工具的全面临床医生教育和程序培训相结合，从而缩短学习曲线并改善程序结果。一个能够捕捉程序指标和患者结果的数位平台可以支持迭代改进并强化上市后证据。

最后，在适当的情况下，采用灵活的商业模式，例如捆绑销售和与结果挂钩的合同，使定价与已证实的结果和系统层面的价值保持一致。与医疗系统合作试行整合护理路径可以提高营运效率，并为更广泛的应用提供案例研究。这些行动协同实施，可以增强韧性，并在日益以结果主导的环境中创造具有竞争力的差异化优势。

严格的多模态调查方法，整合临床证据、相关人员访谈、监管见解和供应链分析，以得出可靠的结论

本分析整合了旨在反映临床实践、监管环境和供应链现状的多模态调查方法的成果。该调查方法结合了同行评审临床文献、手术登记和器械标籤的全面回顾，以确定器械的性能特征和临床应用模式。此外，我们也对介入性心臟病专家、医院采购负责人、监管专家和器械开发主管进行了结构化访谈，以了解该领域对应用驱动因素、未满足需求和营运限制的观点。

作为补充资讯来源，我们审查了监管备案文件、标准指南和已发布的卫生技术评估，以了解不同司法管辖区的证据要求。我们的供应链分析整合了进出口数据趋势、已发布的贸易和关税政策更新以及委託製造的匿名洞察，以绘製采购和製造风险图。我们进行了专利挖掘和研发管线跟踪，以识别新兴技术和研发重点领域。

在整个研究过程中，我们对研究结果进行了跨资讯来源三角检验，以确保研究结果的稳健性，并最大限度地减少单一资讯来源的偏差。证据综合强调了临床相关性、监管效度和商业性适用性，为本文提出的见解和建议奠定了均衡的基础。

简明综合临床、营运和策略驱动因素，确定哪些设备策略将带来持久的临床和商业性价值

冠状动脉疾病治疗设备的发展轨迹取决于技术的成熟度、不断演进的诊疗流程以及对已证实的临床和经济价值予以奖励的环境。血管内影像和生理学的进步使得更精准的病变层面决策成为可能，而靶向治疗设备，从先进的动脉粥样硬化斑块切除系统到药物输送球囊和现代支架平台，则能够应对日益复杂的临床表现。这些临床驱动因素与可及性趋势、付款人审查和供应链压力等营运现实因素相互交织，共同营造出有利于整合解决方案和实证商业化策略的氛围。

那些将设备设计与临床医生工作流程相结合、投资于以结果为导向的证据产生并建立供应链弹性的组织，最有可能实现持久的采用。由于不同地区的证据要求和报销动态各不相同，监管灵活性和针对特定区域的市场策略仍然至关重要。最终，持续的成功取决于能否将技术能力转化为明确的临床效益和系统级价值。

本摘要中的建议提供了蓝图，旨在协调研发、监管、供应链和商业性行动，以满足不断变化的临床医生期望和医疗保健系统需求。企业主管和临床领导者可以参考这些见解，确定优先投资方向，从而显着改善患者照护和组织成果。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用生物可吸收血管支架减少长期併发症
  • 实施人工智慧引导的成像演算法，用于即时病变评估
  • 开发无聚合物药物涂层球囊用于治疗血管再阻塞
  • 机器人 PCI 平台的发展提高了手术精度并减少了透视辐射暴露
  • 用于术前规划的患者专用 3D 列印冠状动脉模型的兴起
  • 抗血栓和抗增生药物联合治疗支架的出现
  • 整合可穿戴心臟监测设备用于 PCI 后患者监测
  • 扩展微导管技术用于复杂分叉病变和慢性完全闭塞的干预
  • 使用光学同调断层扫描与血管内超音波融合来详细表征斑块
  • 可生物降解聚合物涂层的进展可最大程度减少支架置入后的发炎反应

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 冠状动脉疾病治疗设备市场（依设备类型）

  • 动脉粥状硬化斑块切除装置
    • 雷射动脉粥状硬化斑块切除术
    • 眼眶斑块动脉粥状硬化斑块切除术
    • 旋磨动脉粥状硬化斑块切除术
  • 球囊导管
    • 切割球囊导管
    • 药物涂层球囊导管
    • 标准球囊导管
  • 导管导引线
    • 聚合物护套
    • PTFE涂层
    • 未治疗
  • 血管内成像系统
    • 血流储备分数
    • 血管内超音波
    • 光学同调断层扫描
  • 支架
    • 裸金属支架
    • 生物可吸收支架
    • 药物释放型支架

9. 冠状动脉疾病治疗设备市场（依治疗类型）

  • 冠状动脉绕道手术手术
    • 非泵浦
    • 泵浦上
  • 经皮冠状动脉介入治疗
    • 球囊血管成形术
    • 支架置入术

10. 冠状动脉疾病治疗设备市场（依方法）

  • 经股动脉路径
  • 经桡动脉入路

第 11 章：冠状动脉疾病治疗设备市场（依最终使用者）

  • 门诊手术中心
  • 心臟中心
  • 医院

12. 冠状动脉疾病治疗设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章：冠状动脉疾病治疗设备市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 冠状动脉疾病治疗设备市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Biotronik SE & Co. KG
    • Lepu Medical Technology（Beijing）Co., Ltd.
    • Meril Life Sciences Pvt. Ltd.
    • OrbusNeich Medical Company Limited
    • MicroPort Scientific Corporation
    • Cardinal Health, Inc.
Product Code: MRR-4311CE1A33CA

The Coronary Artery Disease Treatment Devices Market is projected to grow by USD 7.26 billion at a CAGR of 5.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.58 billion
Estimated Year [2025] USD 4.84 billion
Forecast Year [2032] USD 7.26 billion
CAGR (%) 5.92%

An authoritative overview of clinical complexities, device innovation pathways, and healthcare priorities reshaping coronary artery disease treatment approaches

The clinical and commercial landscape for coronary artery disease treatment devices is evolving rapidly under the combined influence of technological innovation, shifting procedural preferences, and changing healthcare delivery models. Patients present with increasingly complex anatomies including heavily calcified lesions, chronic total occlusions, and comorbidities that demand nuanced therapeutic approaches. At the same time, clinicians are integrating higher-resolution intravascular imaging and physiology tools into routine decision-making to improve procedural precision and long-term outcomes.

Against this clinical backdrop, device developers and healthcare systems are balancing several imperatives: improving acute procedural success, reducing repeat interventions, and demonstrating durable patient benefit that aligns with payor expectations. Advances in device design, such as refined atherectomy modalities for calcified plaque modification and enhanced drug-delivery balloon technologies to limit restenosis, are complemented by procedural shifts favoring minimally invasive access and shorter hospital stays. These dynamics necessitate cross-functional strategies that link clinical evidence generation, regulatory pathways, reimbursement positioning, and supply chain resilience.

This executive summary synthesizes current drivers affecting coronary devices and highlights structural shifts likely to influence product adoption, clinical practice, and commercial strategy. The analysis places clinical innovation in the context of health system priorities and operational realities, offering a structured foundation for executives and clinical leaders to align investments with evolving unmet needs.

How imaging, physiology, plaque modification, and procedural access trends are converging to redefine therapeutic benchmarks and device adoption in coronary care

Several transformative shifts are reshaping how coronary interventions are conceived, designed, and delivered, and these shifts are accelerating the convergence of imaging, physiology, and therapeutic device capabilities. First, intravascular imaging and physiologic assessment are moving from optional adjuncts to central components of case planning and optimization. The broader adoption of intravascular ultrasound and optical coherence tomography, alongside fractional flow reserve-guided decision-making, has increased lesion-level diagnostic precision and enabled more targeted device selection and deployment strategies.

Second, the growth in complex lesion subsets, particularly calcified coronary disease, has strengthened demand for specialized plaque-modification tools. Atherectomy technologies, including laser, orbital, and rotational modalities, are being refined to improve safety profiles and integration with adjunctive therapies. Concurrently, drug-eluting stent technologies and drug-coated balloons continue to evolve with refined polymer and drug formulations intended to extend durability while minimizing late adverse events. These converging device advancements are prompting hybrid procedural strategies where multiple complementary technologies are deployed within a single case.

Third, procedural access preferences are shifting toward radial approaches in many centers, reducing vascular complications and supporting faster patient throughput. This change is altering device design considerations related to profile, deliverability, and torque control. Finally, the digital and data-driven transformation in healthcare, including procedural analytics and real-world evidence generation, is enabling manufacturers to demonstrate value beyond immediate procedural success by documenting longitudinal outcomes, economic impact, and quality-of-life improvements. Collectively, these shifts are reconfiguring competitive dynamics and establishing new benchmarks for clinical evidence and device performance.

Assessing the cumulative operational, procurement, and regulatory consequences of United States tariff adjustments on coronary device supply chains and pricing strategies

The introduction of tariffs and trade policy changes in the United States in 2025 has exerted a cumulative influence across device sourcing, pricing strategies, and supply chain architecture, prompting industry actors to reassess operational models. Manufacturers with significant component or finished-goods exposure to affected jurisdictions experienced margin pressure, which in turn accelerated initiatives to diversify suppliers and examine nearshoring alternatives. These adaptations emphasized dual-sourcing strategies, qualification of alternative suppliers, and inventory optimization to sustain clinical supply continuity.

In parallel, procurement departments and health systems revisited contracting frameworks to account for potential cost volatility. Longer-term agreements and price-protection clauses have been negotiated to mitigate exposure, while some purchasers adopted more active inventory management and demand forecasting to reduce procurement friction. The tariffs also intensified focus on manufacturing footprint resilience, encouraging investment in regional manufacturing capacity and contract manufacturing partnerships in the Americas.

Regulatory and compliance burdens increased as well, since product relabeling, changes in country-of-origin documentation, and logistics re-routing added administrative complexity. Companies responded by strengthening cross-functional teams combining regulatory affairs, quality, and supply chain expertise to accelerate change controls and maintain regulatory compliance. Strategically, the cumulative impact of tariffs compelled many players to prioritize product designs and sourcing strategies that minimize tariff-exposed components, accelerate local qualification efforts, and use evidence of clinical effectiveness to defend pricing power within constrained reimbursement environments.

Insightful segmentation analysis linking device modalities, treatment pathways, access strategies, and care settings to adoption levers and product positioning

A nuanced segmentation lens reveals distinct opportunity zones and operational considerations across device type, treatment modality, procedural approach, and end-user setting. When devices are categorized by type, the analysis must account for atherectomy systems-which include laser, orbital, and rotational iterations-each optimized for different plaque morphologies and clinical scenarios. Balloon catheter technologies span cutting, drug-coated, and standard designs, with drug-coated balloons growing in relevance for in-stent restenosis and small-vessel disease. Guidewire variants such as polymer-jacketed, PTFE-coated, and untreated options continue to serve differentiated procedural roles depending on lesion complexity and deliverability needs. Intravascular imaging systems encompass fractional flow reserve platforms, intravascular ultrasound, and optical coherence tomography, each contributing unique diagnostic resolution that informs device selection and deployment technique. Stent platforms include bare metal constructs, bioresorbable scaffolds, and drug-eluting designs, with trade-offs in acute scaffolding, long-term vessel healing, and device longevity shaping clinician preference.

Examining treatment types reveals that coronary artery bypass grafting remains an essential option for specific anatomic and multivessel presentations, with off-pump and on-pump strategies retaining particular clinical rationales. Percutaneous coronary intervention continues to expand in scope through adjunctive technologies and procedural refinements, whether performed with balloon angioplasty alone or combined with stenting. The choice between surgical and percutaneous pathways is increasingly individualized through multidisciplinary heart team assessment and enhanced lesion-level diagnostics.

Approach selection between transfemoral and transradial access frames device design and procedural logistics, since radial-first practices prioritize low-profile, highly deliverable devices, while femoral access may accommodate bulkier adjunctive tools. End-user segmentation across ambulatory surgical centers, cardiac centers, and hospitals reflects varying procedural complexity, resource intensity, and reimbursement considerations, creating differentiated adoption pathways. Each segmentation axis requires tailored evidence generation, pricing strategies, and service models to optimize uptake across heterogeneous clinical settings.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory pathways, adoption priorities, and localized commercialization strategies

Regional dynamics create differentiated demand drivers and operational imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific, shaping regulatory pathways, reimbursement landscapes, and clinical practice patterns. In the Americas, procedural innovation often intersects with consolidated payer systems and large hospital networks that emphasize real-world outcomes and cost-effectiveness; there is strong appetite for demonstrable improvements in procedural efficiency and reduction in repeat interventions. This context incentivizes manufacturers to invest in robust post-market evidence and provider education programs that translate device advantages into measurable clinical and economic value.

In Europe, the Middle East and Africa, heterogeneous regulatory and reimbursement frameworks necessitate localized market-entry strategies. Western European markets frequently require rigorous health technology assessments and country-specific clinical evidence, while emerging markets in the broader region may prioritize cost containment and scalable solutions that support expanding procedural capacity. Manufacturers navigating this geography must align pricing, clinical support, and regulatory submissions to the expectations of diverse national health systems.

The Asia-Pacific region presents a combination of high-volume procedural markets and rapidly advancing clinical capabilities, with several countries investing significantly in interventional cardiology infrastructure. Local manufacturing and partnerships are particularly influential here, as regional supply chain integration and regulatory alignment can accelerate adoption. Across all regions, demographic shifts toward aging populations and rising cardiovascular disease burden drive sustained clinical demand, but regional reimbursement, provider training, and health system priorities will determine the pace and nature of device uptake.

How product integration, clinical evidence, supply chain robustness, and commercialization expertise define competitive advantage among coronary device manufacturers

Competitive dynamics among companies active in coronary device development are defined by a blend of technology leadership, clinical evidence generation, manufacturing scale, and go-to-market sophistication. Leading firms prioritize integrated portfolios that pair therapeutic devices with diagnostic platforms, enabling bundled procedural solutions that support better case selection and optimization. Investment in clinical trials, registries, and post-market surveillance continues to be a differentiator, as health systems increasingly reward demonstrable long-term outcomes and economic value.

Strategic partnerships, licensing agreements, and selective acquisitions are common tools to access complementary technologies, expand geographic reach, or accelerate entry into emerging procedural niches. Supply chain resilience and regulatory agility are prominent operational priorities, with companies enhancing redundancy through contract manufacturing networks and regional production capacity. Talent investment in clinical affairs, evidence generation, and reimbursement expertise is equally important to translate device performance into adoption and favorable procurement outcomes.

Product differentiation increasingly centers on deliverability, lesion-specific performance, and adjunctive diagnostic compatibility. Companies that offer clinician training programs, procedural support, and robust data capture capabilities are better positioned to shorten adoption curves and build long-term clinical endorsement. As the competitive landscape matures, winners will be those who can integrate technical innovation with pragmatic commercialization models that reflect clinician workflows and payer expectations.

Practical strategic imperatives for leaders to align product innovation, supply chain resilience, and evidence-driven commercialization for sustainable growth

Industry leaders should prioritize a portfolio strategy that emphasizes clinically meaningful differentiation, regulatory foresight, and supply chain adaptability to capture sustained value. First, invest selectively in device improvements that address high-impact clinical gaps such as calcified lesions, small-vessel disease, and restenosis, while ensuring that design changes enhance deliverability for radial approaches. Coordinated clinical programs that generate both randomized evidence and real-world registry data will strengthen value propositions with clinicians and payers, supporting broader adoption and reimbursement alignment.

Second, build resilient sourcing architectures by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff-aware procurement clauses to mitigate policy-driven cost shocks. Cross-functional teams should own rapid change-control processes to accelerate supplier onboarding while maintaining regulatory compliance. Third, couple product launches with comprehensive clinician education and procedural training that integrate intravascular imaging and physiology tools, thereby shortening learning curves and improving procedural outcomes. Digital platforms that capture procedural metrics and patient outcomes can support iterative improvement and strengthen post-market evidence.

Finally, adopt flexible commercial models that align pricing with demonstrated outcomes and system-level value, including bundled agreements and outcome-linked contracts where appropriate. Collaboration with health systems to pilot integrated care pathways can surface operational efficiencies and provide reference cases for wider adoption. These actions, executed in parallel, will enhance resilience and create defensible differentiation in an increasingly outcome-driven environment.

A rigorous, multi-modal research methodology integrating clinical evidence, stakeholder interviews, regulatory insights, and supply chain analysis to ensure robust conclusions

This analysis synthesizes insights drawn from a multi-modal research approach designed to reflect clinical practice, regulatory context, and supply chain realities. The methodology combined a comprehensive review of peer-reviewed clinical literature, procedural registries, and device labeling to establish device performance characteristics and clinical application patterns. In addition, structured interviews were conducted with interventional cardiologists, hospital procurement leaders, regulatory specialists, and device development executives to capture frontline perspectives on adoption drivers, unmet needs, and operational constraints.

Supplementary sources included a review of regulatory filings, standards guidance, and published health technology assessments to understand evidence expectations across jurisdictions. Supply chain analysis incorporated import-export data trends, published policy updates related to trade and tariffs, and anonymized insights from contract manufacturers to map procurement and manufacturing risk. Patent landscaping and pipeline tracking were used to identify emerging technologies and R&D focus areas.

Throughout the research process, findings were triangulated across sources to ensure robustness and to minimize single-source bias. Evidence synthesis emphasized clinical relevance, regulatory plausibility, and commercial applicability, providing a balanced foundation for the insights and recommendations presented herein.

A concise synthesis of clinical, operational, and strategic drivers that will determine which device strategies deliver enduring clinical and commercial value

The trajectory of coronary artery disease treatment devices is defined by technological refinement, procedural evolution, and an environment that rewards demonstrable clinical and economic value. Advances in intravascular imaging and physiology are enabling more precise, lesion-level decision-making, while targeted therapeutic devices-ranging from advanced atherectomy systems to drug-delivery balloons and modern stent platforms-are addressing increasingly complex clinical presentations. These clinical drivers intersect with operational realities such as access trends, payer scrutiny, and supply chain pressures, creating a landscape that favors integrated solutions and evidence-rich commercialization strategies.

Organizations that align device design with clinician workflow, invest in outcome-focused evidence generation, and build supply chain resilience will be best positioned to capture durable adoption. Regulatory agility and region-specific market approaches remain essential as jurisdictions vary in evidence requirements and reimbursement dynamics. Ultimately, sustained success will hinge on the ability to translate technical performance into clear clinical benefit and system-level value, enabling providers and payers to justify adoption amid competing budgetary and operational priorities.

The recommendations in this summary provide a roadmap for aligning R&D, regulatory, supply chain, and commercial actions to meet evolving clinician expectations and health system demands. Executives and clinical leaders can leverage these insights to prioritize investments that yield meaningful improvements in patient care and organizational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of bioresorbable vascular scaffolds for reduced long-term complications
  • 5.2. Implementation of AI-guided imaging algorithms for real-time lesion assessment
  • 5.3. Development of polymer-free drug-coated balloons for in-stent restenosis management
  • 5.4. Growth of robotic PCI platforms for enhanced procedural precision and reduced fluoroscopy exposure
  • 5.5. Rise of patient-specific 3D printed coronary artery models for pre-operative planning
  • 5.6. Emergence of dual therapy stents combining antithrombotic and antiproliferative agents
  • 5.7. Integration of wearable cardiac monitoring devices for post-PCI patient surveillance
  • 5.8. Expansion of microcatheter technologies for complex bifurcation and chronic total occlusion interventions
  • 5.9. Use of optical coherence tomography fused with intravascular ultrasound for detailed plaque characterization
  • 5.10. Advancements in biodegradable polymer coatings to minimize inflammatory response after stent implantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Artery Disease Treatment Devices Market, by Device Type

  • 8.1. Atherectomy Device
    • 8.1.1. Laser Atherectomy
    • 8.1.2. Orbital Atherectomy
    • 8.1.3. Rotational Atherectomy
  • 8.2. Balloon Catheter
    • 8.2.1. Cutting Balloon Catheter
    • 8.2.2. Drug-Coated Balloon Catheter
    • 8.2.3. Standard Balloon Catheter
  • 8.3. Guidewire
    • 8.3.1. Polymer-Jacketed
    • 8.3.2. PTFE-Coated
    • 8.3.3. Untreated
  • 8.4. Intravascular Imaging System
    • 8.4.1. Fractional Flow Reserve
    • 8.4.2. Intravascular Ultrasound
    • 8.4.3. Optical Coherence Tomography
  • 8.5. Stent
    • 8.5.1. Bare Metal Stent
    • 8.5.2. Bioresorbable Scaffold
    • 8.5.3. Drug Eluting Stent

9. Coronary Artery Disease Treatment Devices Market, by Treatment Type

  • 9.1. Coronary Artery Bypass Grafting
    • 9.1.1. Off Pump
    • 9.1.2. On Pump
  • 9.2. Percutaneous Coronary Intervention
    • 9.2.1. With Balloon Angioplasty
    • 9.2.2. With Stenting

10. Coronary Artery Disease Treatment Devices Market, by Approach

  • 10.1. Transfemoral Approach
  • 10.2. Transradial Approach

11. Coronary Artery Disease Treatment Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Coronary Artery Disease Treatment Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Coronary Artery Disease Treatment Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Coronary Artery Disease Treatment Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Terumo Corporation
    • 15.3.5. Biotronik SE & Co. KG
    • 15.3.6. Lepu Medical Technology (Beijing) Co., Ltd.
    • 15.3.7. Meril Life Sciences Pvt. Ltd.
    • 15.3.8. OrbusNeich Medical Company Limited
    • 15.3.9. MicroPort Scientific Corporation
    • 15.3.10. Cardinal Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CORONARY ARTERY DISEASE TREATME